India, July 22 -- With dengue continuing to pose a major public health challenge during India's monsoon season, the approval of QDENGA, the country's first dengue vaccine, marks a significant milestone in disease prevention. Developed by Takeda, the vaccine has been approved for people aged 4 to 60 years and is designed to protect against all four dengue virus serotypes.

While the approval offers new hope in reducing severe illness and hospitalisations, many questions remain about who should get vaccinated, how effective it is, whether it is safe for everyone and if mosquito precautions are still necessary. HT Lifestyle reached out to infectious disease experts to answer these key questions and explain what the vaccine means for India's ...